Multiple factors are contributing to bottlenecks in the global supply of COVID-19 vaccines — ensuring equitable global access will require multiple, simultaneous policy approaches.

**Suspend Patents:** Non-enforcement of patents (i.e. TRIPS waiver) will maximize manufacturing potential.

**Transfer Technology:** Vaccines are complex to make, deep technology transfer is required to scale up manufacturing at qualified facilities.

**Lift Embargoes:** Ensure companies are able to export raw materials that are the building blocks of vaccines as well as ‘fill and finish’ supplies such as glass vials and syringes.

**Invest in Manufacturing Capacity:** Make long-term investments to build vaccine manufacturing capacity in Africa and Latin America.

**Continue R&D:** Fund ongoing efforts to develop vaccines with more favorable profiles for widespread manufacturing.

**Share Surplus:** Countries who have over-purchased vaccine doses should immediately begin sharing — regardless of contractual prohibitions against doing so.

May 2021